Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Holmes

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Clinical Breast Cancer|August 7, 2017
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast CancerCynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.
Clinical Breast Cancer|December 17, 2008
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancerStephen Jones, Christopher Stokoe, Mark Sborov, et al.
Research Involvement and Engagement|September 29, 2023
Dementia resources for eating, activity, and meaningful inclusion (DREAM) toolkit co-development: process, output, and lessons learnedLaura E Middleton, Shannon Freeman, Chelsea Pelletier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyStephen E Jones, James Cantrell, Svetislava Vukelja, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerStephen E Jones, Michael A Savin, Frankie Ann Holmes, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Breast Cancer|August 7, 2017
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast CancerCynthia Osborne, Jagathi D Challagalla, Charles F Eisenbeis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.
Clinical Breast Cancer|December 17, 2008
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancerStephen Jones, Christopher Stokoe, Mark Sborov, et al.
Research Involvement and Engagement|September 29, 2023
Dementia resources for eating, activity, and meaningful inclusion (DREAM) toolkit co-development: process, output, and lessons learnedLaura E Middleton, Shannon Freeman, Chelsea Pelletier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudyStephen E Jones, James Cantrell, Svetislava Vukelja, et al.
The Lancet. Oncology|September 7, 2013
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyStephen E Jones, Rufus Collea, Devchand Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Stephen Jones, Frankie Ann Holmes, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerStephen E Jones, Michael A Savin, Frankie Ann Holmes, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Pageof 5